TNFSF10 and prostate cancer: Based on the information that Dox can synergise with TRAIL to elicit cytotoxicity in various types of tumours (Hannun, 1997; Los et al, 1997; Keane et al, 1999; Muzutani et al, 1999; Yamanaka et al, 2000; Lacour et al, 2001; Wu et al, 2002) as well as that PL is able to interfere with tumour growth, we tried to explore the potential of the combination treatment of Dox and PL against prostate cancer.